|
Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 243 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Small molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs currently approved for various tumor types. This promise of high commercial rew.....
Introduction Small molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs currently approved for various tumor types. This promise of high commercial rewards has driven considerable pipeline activity for small molecule targeted therapies within cancer. Scope *Examination of the small molecule targeted cancer therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates *Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions *Segmentation and analysis of the current small molecule targeted cancer therapies pipeline by developmental phase, drug target and company *Insight and analysis of market potential including commercial opportunity and discussion of unmet needs Highlights There are currently 288 small molecule targeted therapies in development for cancer. Single-target signal transduction inhibitors and multi-targeted inhibitors form the majority of the pipeline, accounting for 28% and 28% of the pipeline, respectively. These two classes each contain a number of agents with novel mechanisms of action. Progress in understanding of how to target tyrosine kinases with small molecules has benefited oncology drug discovery. Efforts are continuing to develop small molecule inhibitors against other kinases that are more selective and capable of overcoming drug resistance. Around 30 distinct targets are currently being tested in Phase I clinical trials. The late-phase small molecule therapies directed towards novel targets are forecast to generate sales of $3,635m by 2019 across the seven major markets. Abiraterone (Cougar Biotechnology/Johnson & Johnson) and BSI-201 (BiPar Sciences/Sanofi-Aventis) are forecast to achieve the highest sales by 2019. Reasons to Purchase *Identify key drugs and companies within the small molecule targeted cancer therapies pipeline based on sales forecasts and Datamonitor drug assessment *Assess the shifting small molecule targeted cancer therapies market dynamic and how future treatment will incorporate pipeline products *Identify licensing opportunities based on company portfolio and market needs [Studien Infos ausblenden] |
|||||||||||
|
Overview 1 Catalyst 1 Summary 1 About Datamonitor Healthcare 2 About the Oncology pharmaceutical analysis team 2 Executive Summary 3 Strategic scoping and focus 3 Datamonitor insight into the small molecule molecular targeted therapy market 3 Related reports 5 Upcoming related reports 5 Table of Contents 6 1. Pipeline Overview and Dynamics 7 Key findings 7 Pipeline overview 7 Pipeline summary 7 There are 32 small molecule targeted therapies in late-phase development for cancer 7 Datamonitor forecasts 9 Single target signal transduction inhibitors and multi-targeted inhibitors dominate the current small molecule MTT pipeline 9 Comparative forecasts 10 Datamonitor drug assessment summary 12 Key companies involved in the biologic molecular targeted therapies pipeline 15 Pfizer 15 Novartis 17 Bristol-Myers Squibb 19 Key R&D company strategies 21 Developers of small molecule targeted therapies are maximizing their revenues through indication expansion across multiple tumor types 21 The development of companion diagnostics to improve chances of approval 21 2. Small molecule targeted cancer therapies - Market Potential 22 Key findings 22 Targeted therapies overview 22 Definition 22 Targeted therapies provide clues into the biology behind cancer 22 Conventional therapies are less cancer cell-specific 23 Increased specificity for targets could lead to the development of drugs with greater efficacy 23 Small molecules 23 Small molecules targeting tyrosine kinases have been a significant development in oncology drug discovery 23 Classification of pipeline products 24 Angiogenesis inhibitor/vascular disrupting agents 24 Angiogenesis is known to be aberrant in tumor cell proliferation 24 The process of angiogenesis 24 Angiogenesis inhibitors can target a number of pathways as viable antitumor agents 25 Three small molecule angiogenesis inhibitors exist on the market 26 Single-target signal transduction inhibitors 27 A plethora of potential targets exist along the signaling cascade 27 Three small molecule single target signal transduction have been approved in cancer 27 Multi-targeted inhibitors 28 Multi-targeted inhibitors have certain theoretical advantages over single targeted agents 28 The underlying mechanism of multi-targeted kinase inhibition is still unclear 28 Several multi-targeted inhibitors have been approved for cancer 29 Cell cycle and apoptosis targeted agents 30 Cell death can be induced via a number of different pathways 30 To date, only one apoptosis stimulator has reached the market 30 Immunomodulatory and immunoconjugated therapeutics 31 Research into immunomodulatory agents for cancer has been challenging owing to the complexities of the host-tumor relationship 31 There are two small molecule targeted immunomodulatory/immunoconjugated agents approved in oncology 31 Epigenetic modulators 32 Epigenetic dysregulation can contribute to tumor progression 32 There is one small molecule epigenetic modulator approved for oncology 33 Differences between biologic and small molecule targeted therapeutics 34 3. R&D Approach 35 Key findings 35 Clinical trial design for molecular targeted therapies 35 Patient selection 35 New generation compounds specific to tumor pathways are set to alter the traditional method of patient selection 35 More specific selection of patients in clinical trials may improve a drug's chances of commercial success and keep costs down 36 Sufficient follow-up is necessary to establish true clinical benefit 36 Clinical trial endpoints in oncology 36 Overall survival 37 Disease-free survival 37 Overall response rates 37 Progression-free survival 38 Disease control rate 38 Toxicity 38 Time to tumor progression 38 4. Pipeline Analysis & Forecasts: Angiogenesis Inhibitors and Vascular Disrupting Agents 39 Key findings 39 Overview of angiogenesis inhibitors 39 Pipeline summary 39 Late-phase pipeline of angiogenesis inhibitors and vascular-disrupting agents 39 Comparative forecasts 40 Definition of current comparator therapy 43 Sutent (sunitinib; Pfizer) 43 ASA404 (Antisoma/Novartis) 44 Drug overview 44 Drug profile 45 Key historical events 45 Clinical trial data 46 ASA404 is effective and well tolerated in NSCLC patients with both squamous and non-squamous histology 47 The addition of ASA404 to Taxotere does not have a significant impact on median survival in a Phase II study in castration-resistant prostate cancer 49 ASA404 fails its Phase III ATTRACT-1 trial in previously untreated NSCLC patients 50 SWOT analysis 51 Datamonitor drug assessment summary for ASA404 52 Clinical and commercial attractiveness 52 Failure of ATTRACT-1 trial comes as a serious blow to ASA404's chances of success in NSCLC patients with squamous cell histology 52 ASA404's combination with Taxotere will have to show very impressive results 53 Antisoma's partnership with Novartis will bolster ASA404's position in the cancer market 53 Forecasts to 2019 53 Cilengitide (Merck KGaA) 54 Drug overview 54 Drug profile 55 Key historical events 55 Clinical trial data 56 Cilengitide may offer added benefit to standard treatment for glioma 58 Cilengitide fails to confer a survival benefit over Taxotere in Stage IV NSCLC patients 59 SWOT analysis 60 Datamonitor drug assessment summary 61 Clinical and commercial attractiveness 62 Cilengitide is the only integrin antagonist in late-phase development for cancer 62 Selecting patients based on molecular markers could improve the chances of success 63 Fierce competition from Avastin could hamper uptake 63 Other targeted therapies could also pose a threat to cilengitide's commercial success 63 Intravenous formulation may be a disadvantage compared to Temodar 63 Merck KGaA's commercial expertise will assist in the commercialization of cilengitide 64 Forecasts to 2019 64 5. Pipeline Analysis & Forecasts: Cell cycle/ apoptosis targeted agents 65 Key findings 65 Overview of cell cycle/apoptosis targeted agents 65 Pipeline summary 65 Late-phase pipeline of cell cycle and apoptosis targeted agents 65 Comparative forecasts 66 Definition of current comparator therapy 72 Velcade (bortezomib; Takeda/Johnson & Johnson) 72 Alvocidib (flavopiridol; Sanofi-Aventis) 73 Drug overview 73 Drug profile 73 Key historical events 74 Clinical trial data 75 Optimization of alvocidib's dosing schedule has reawakened interest in the drug 75 Single-agent alvocidib induces responses in heavily pretreated CLL patients with unfavorable cytogenetics 76 Alvocidib has also shown promise in early stages studies in combination with fludarabine and Rituxan 77 SWOT analysis 77 Datamonitor drug assessment score card for alvocidib 78 Clinical and commercial attractiveness 79 Alvocidib has shown encouraging signs of activity in difficult-to-treat patients 79 Sanofi-Aventis will have to overturn negative perceptions of alvocidib's clinical development in CLL 80 Arzerra could prove to be a major competitor for alvocidib, given its more favorable toxicity profile 80 Forecasts to 2019 81 Abiraterone (CB-7630; Cougar Biotechnology/BTG/Johnson & Johnson) 81 Drug overview 82 Drug profile 82 Key historical events 82 Clinical trial data 83 Phase II results show abiraterone to confer encouraging efficacy in both chemotherapy-naïve and in heavily pretreated castration-resistant prostate cancer 84 SWOT analysis 87 Datamonitor drug assessment summary for abiraterone 88 Clinical and commercial attractiveness 89 Encouraging Phase II data have resulted in a media furor over abiraterone, starting with controversy over use of the term "hormone refractory" 89 Efficacy in a heavily pretreated patient population is striking in itself 90 Expansion into the first-line metastatic castration-resistant prostate cancer setting significantly increases abiraterone's commercial potential 91 Forecasts to 2019 91 BSI-201 (BiPar Sciences/Sanofi-Aventis) 92 Drug overview 92 Drug profile 93 Key historical events 94 Clinical trial data 95 BSI-201 has shown promising activity in its Phase II trial for triple-negative breast cancer 96 SWOT analysis 97 Datamonitor drug assessment summary for BSI-201 98 Clinical and commercial attractiveness 98 High potential to alter the treatment landscape for triple-negative breast cancer 98 BSI-201's mechanism of action could usher in a new generation of targeted PARP inhibitors in cancer 99 High unmet need in triple-negative breast cancer should assist in the commercial success of BSI-201 99 Fierce competition with several agents for a share of the triple-negative breast cancer market 99 Sanofi-Aventis's commercial expertise will bolster BSI-201's position in the market 99 Forecasts to 2019 99 Phenoxodiol (Marshall Edwards/Novogen) 100 Drug overview 100 Drug profile 101 Key historical events 101 Clinical trial data 102 The combination of phenoxodiol and cisplatin appears to be effective in ovarian cancer 103 SWOT analysis 104 Clinical and commercial attractiveness 105 Marshall Edwards's financial difficulties could affect the clinical development of phenoxodiol 105 Trabedersen (AP-12009; Antisense Pharma) 105 Drug overview 105 Drug profile 105 Key historical events 106 Clinical trial data 107 Trabedersen shows significant Phase II survival results in second-line glioma patients 107 SWOT analysis 109 Datamonitor drug assessment summary for trabedersen in 2010 109 Clinical and commercial attractiveness 110 Trabedersen's chances of approval are high if Phase III results are favorable 110 Trabedersen will be received with an air of skepticism due to past experiences with antisense oligonucleotides 111 Trabedersen will only realize its complete commercial potential with indication expansion 111 Competition from Avastin could restrict trabedersen's uptake for glioma 111 Securing a marketing partner will be crucial for trabedersen's success 112 Forecasts to 2019 112 Zibotentan (ZD-4054; AstraZeneca) 112 Drug overview 113 Drug profile 113 Key historical events 114 Clinical trial data 114 Phase II trial results show zibotentan to confer improved survival over placebo, with a possible effect on bone metastases 115 SWOT analysis 116 Datamonitor drug assessment summary for ZD-4054 117 Clinical and commercial attractiveness 118 Use of placebo as a comparator is controversial 118 Effect on bone metastases may result in lower overall cost of treatment 119 Xinlay has already failed where zibotentan is now being investigated 119 AstraZeneca has extensive experience in the prostate cancer market 119 Forecasts to 2019 119 6. Pipeline Analysis & Forecasts: Multi-targeted inhibitors 121 Key findings 121 Overview of multi-targeted inhibitors 121 Pipeline summary 121 Late-phase pipeline of small molecule multi-targeted inhibitors 121 Comparative forecasts 123 Definition of current comparator therapy 127 Gleevec/Glivec (imatinib; Novartis) 127 Enzastaurin (LY-31761; Eli Lilly) 128 Drug overview 128 Drug profile 129 Key historical events 129 Clinical trial data 130 Enzastaurin shows marginal single-agent activity in relapsed/refractory DLBCL 132 SWOT analysis 133 Datamonitor drug assessment summary for enzastaurin 134 Clinical and commercial attractiveness 135 The response rates in the Phase II trial are not very impressive 135 Enzastaurin may have to compete with Afinitor and Revlimid if approved as a maintenance therapy for DLBCL 136 Forecasts to 2019 136 Linifanib (ABT-869; Abbott) 137 Drug overview 137 Drug profile 137 Key historical events 138 Clinical trial data 139 Phase II results show linifanib to confer clinical benefit in both the first- and second-line treatment settings for advanced hepatocellular carcinoma 139 SWOT analysis 140 Datamonitor drug assessment score card for linifanib 141 Clinical and commercial attractiveness 142 By excluding second-line patients from the ongoing Phase III trial, linifanib could show equivalent or superior survival results to standard-of-care Nexavar in hepatocellular carcinoma 142 Other pipeline agents in development for hepatocellular carcinoma pose a significant threat to linifanib... 143 ...therefore Abbott could also target alternative treatment settings or patient subgroups within hepatocellular carcinoma to differentiate linifanib 143 Forecasts to 2019 143 Masitinib (AB-1010; AB Science) 144 Drug overview 144 Drug profile 144 Key historical events 145 Clinical trial data 146 Phase II trial shows a first-line combination of Gemzar and masitinib to confer similar efficacy to Gemzar monotherapy and other Gemzar-based combinations in pancreatic cancer 147 Encouraging Phase II results for masitinib in first-line Gleevec-naïve gastrointestinal stromal tumors 148 SWOT analysis 149 Datamonitor drug assessment summary for masitinib 150 Clinical and commercial attractiveness 150 If Phase II results can be replicated in the ongoing Phase III study, then approval will be likely in pancreatic cancer 150 Masitinib should in theory confer greater efficacy alongside Gemzar than Tarceva due to inhibition of multiple pathways in pancreatic cancer 151 There is room for a more effective therapy than Gleevec if the ongoing Phase III trial for first-line GIST proves to be favorable 151 Competition from several high profile drugs in clinical development for front-line gastrointestinal stromal tumors 151 AB Science will need to price masitinib competitively in order to enhance its uptake 151 In order to optimize masitinib's commercial potential, AB Science should seek a partner experienced in the human oncology market 152 Forecasts to 2019 152 Midostaurin (PKC412; Novartis) 153 Drug overview 153 Drug profile 153 Key historical events 154 Clinical trial data 155 Midostaurin shows promising evidence of efficacy in AML patients with wild-type and mutant Flt3 155 SWOT analysis 157 Datamonitor drug assessment summary for midostaurin 157 Clinical and commercial attractiveness 158 Patients with Flt3 mutations represent a good target population for midostaurin 158 Midostaurin would benefit from a more convenient commercially available companion diagnostic 159 Novartis's capabilities in niche hematological indications will boost midostaurin's commercial potential 159 Forecasts to 2019 159 Perifosine (KRX-040; AEterna Zentaris/Keryx Biopharmaceuticals) 160 Drug overview 160 Drug profile 161 Key historical events 161 Clinical trial data 162 Phase I/II trial finds perifosine to be well tolerated in patients with advanced multiple myeloma 164 Phase II study shows perifosine to have encouraging activity in heavily pretreated metastatic colorectal cancer 166 SWOT analysis 167 Datamonitor drug assessment summary for perifosine 168 Clinical and commercial attractiveness 169 Perifosine will have to demonstrate a highly favorable toxicity and efficacy profile in its Phase III trial for CRC 169 Keryx's strategy of targeting heavily pretreated patients may increase its prospect of approval in CRC 170 Perifosine could face barriers to uptake in cost-conservative healthcare markets 170 Perifosine will face fierce competition from several agents in the late-phase colorectal cancer pipeline 170 Absence of a Big Pharma partner will restrict perifosine's success 170 Forecasts to 2019 171 PF-2341066 (Pfizer) 171 Drug overview 172 Drug profile 172 Key historical events 173 Clinical trial data 173 PF-2341066 appears to demonstrate encouraging clinical activity in NSCLC patients harboring the EML4-ALK translocation 174 SWOT analysis 176 Datamonitor drug assessment summary for PF-2341066 176 Clinical and commercial attractiveness 177 PF-2341066 offers the opportunity to optimize treatment of NSCLC 177 PF-2341066 will need to demonstrate superior efficacy over Taxotere or Alimta to encourage uptake 178 Pfizer's strategy to progress PF-2341066 straight into Phase III trials may be risky 178 PF-2341066's label could restrict its commercial potential 178 Pfizer's growing position in the oncology market will assist in PF-2341066's success 178 Forecasts to 2019 179 Zactima (vandetanib; AstraZeneca) 179 Drug overview 180 Drug profile 180 Key historical events 180 Clinical trial data 181 Zactima shows promising results in the treatment of thyroid cancer 184 Multiple Phase III trials for NSCLC underway 186 The combination of Zactima with Taxotere and with Iressa appeared to be well-tolerated in the second-line setting 187 Zactima fails to demonstrate superior efficacy over Tarceva in the ZEST trial 189 AstraZeneca withdraws filing for Zactima in combination with chemotherapy in NSCLC over a lack of survival benefits 190 Zactima is being examined as a monotherapy in the third-line treatment of NSCLC in the ZEPHYR study 191 SWOT analysis 191 Clinical and commercial attractiveness 192 The head-to-head trial against Tarceva in NSCLC was a high-risk strategy 192 High unmet need in NSCLC could have been profitable for Zactima 192 It is unclear how AstraZeneca will recover the development costs of the NSCLC trials 192 Zactima is in Phase III development for medullary thyroid cancer 193 Forecasts to 2019 193 XL-184 (Exelixis/ Bristol-Myers Squibb) 193 Drug overview 193 Drug profile 193 Key historical events 194 Clinical trial data 195 Little information is available on XL-184's clinical activity in medullary thyroid cancer 196 XL-184 demonstrates encouraging activity in second-line or higher glioma 197 SWOT analysis 199 Datamonitor drug assessment summary for XL-184 200 Clinical and commercial attractiveness 201 XL-184 could satisfy an unmet need in the treatment of thyroid cancer 201 Uncertainty over XL-184's effectiveness in thyroid cancer 201 Tolerability will be critical to XL-184's success in second-line or higher thyroid cancer 202 Indication expansion will be needed to recover clinical development for XL-184 202 Activity in glioma could increase the commercial potential of XL-184 202 Fierce competition from other late-phase pipeline drugs 202 Bristol-Myers Squibb's partnership with Exelixis will be crucial to XL-184's success 203 Forecasts to 2019 203 6. Pipeline Analysis & Forecasts: Single-target signal transduction inhibitors 204 Key findings 204 Overview of single-target signal transduction inhibitors 204 Pipeline summary 204 Late-phase pipeline of small molecule single-target signal transduction inhibitors 204 Comparative forecasts 204 Definition of current comparator therapy 207 Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche/Chugai) 207 OSI-906 (OSI Pharmaceuticals) 208 Drug overview 208 Drug profile 209 Key historical events 209 Clinical trial data 210 Phase I continuous dosing trial shows OSI-906 to be tolerable in advanced solid tumors 210 SWOT analysis 211 Clinical and commercial attractiveness 211 Lack of clinical trial data makes it difficult to assess OSI-906 211 PLX-4032 (Plexxikon/Roche) 212 Drug overview 212 Drug profile 212 Key historical events 213 Clinical trial data 214 Phase I trial shows early signs of efficacy in second-line metastatic melanoma 214 SWOT analysis 216 Datamonitor drug assessment summary for PLX-4032 217 Clinical and commercial attractiveness 217 PLX-4032 has the potential to treat a highly underserved population should its early signs of efficacy be reproduced in Phase III studies 217 Phase I results should be greeted with caution 218 Step towards more individualized therapies 218 PLX-4032 will be profitable for Plexxikon and Roche should Phase III trials be successful 218 Roche's marketing power will provide the necessary platform for PLX-4032's success 218 Forecasts to 2019 219 7. Innovative Early-Stage Approaches 220 Key findings 220 Overview of early-stage innovative projects 220 Aurora protein kinase 222 Kinesin-spindle protein (KIF11) 223 Mitogen activated protein kinase/ extracellular signal-regulated kinase (MEK) 224 The future of treatment with small molecule targeted therapies 224 Improvements in diagnostics and prognostic analysis will enhance cost-effectiveness of treatment 224 Enhanced preventative strategies will ease the disease burden 224 Increased understanding of cancer evolution should result in a large range of potential drug targets 224 Bibliography 226 Journals 226 Websites 234 Datamonitor reports 237 APPENDIX 239 Epidemiology forecasts 239 Product forecasts 239 About Datamonitor 242 About Datamonitor Healthcare 242 About the Disease analysis team 242 Datamonitor consulting 243 Disclaimer 243 List of Tables Table 1: Late-phase pipeline of small molecule molecular targeted therapies (MTTs) for cancer, 2009 7 Table 2: Sales forecasts for late-phase small molecule MTTs in the seven major markets ($m), 2010-19 11 Table 3: Pfizer's marketed and pipeline small molecule targeted therapy oncology portfolio, 2010 16 Table 4: Novartis's marketed and pipeline small molecule targeted therapy oncology portfolio 2010 17 Table 5: Bristol-Myers Squibb's marketed and pipeline small molecule targeted therapy oncology portfolio, 2010 20 Table 6: Approved small molecule angiogenesis inhibitors, 2010 26 Table 7: Approved small molecule single target signal transduction inhibitors, 2010 28 Table 8: Approved small molecule multi-targeted inhibitors, 2010 29 Table 9: Approved small molecule cell cycle/apoptosis targeted agents, 2010 31 Table 10: Approved small molecule targeted immunomodulatory/immunoconjugated therapeutic, 2010 32 Table 11: Approved small molecule targeted epigenetic modulator, 2010 33 Table 12: Differences between biologic and small molecule molecular targeted therapies (MTTs) for cancer 34 Table 13: Late-phase small molecule angiogenesis inhibitors/vascular-disrupting agents pipeline, 2010 40 Table 15: Sales forecasts small molecule angiogenesis inhibitors and vascular disrupting agents in late phase development for cancer in the seven major markets ($m), 2010-2019 42 Table 16: Sutent - drug profile, 2010 44 Table 17: ASA404 - drug profile, 2010 45 Table 18: ASA404: key historical events, 2005-09 46 Table 19: Clinical development of ASA404 in cancer, 2010 47 Table 20: Sales forecast for ASA404 in cancer across the seven major markets ($m), 2010-2019 54 Table 21: Cilengitide - drug profile, 2010 55 Table 22: Cilengitide: key historical events, 1999-2009 56 Table 23: Clinical development of cilengitide, 2010 57 Table 24: Sales forecast for cilengitide in cancer across the seven major markets ($m), 2010-2019 64 Table 25: Late-phase small molecule cell cycle/apoptosis targeted agents pipeline in cancer, 2010 66 Table 30: Sales forecasts for cell cycle/apoptosis targeted agents in late-phase development for cancer in the seven major markets ($m), 2010-2019 71 Table 31: Velcade - drug profile, 2010 73 Table 32: Alvocidib - drug profile, 2010 74 Table 33: Alvocidib: key historical events, 2004-2010 74 Table 34: Clinical development of alvocidib in chronic lymphocytic leukemia (CLL), 2010 75 Table 35: Phase I dose-escalating study of alvocidib in combination with chemotherapy in patients with indolent B-cell non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma 77 Table 36: Sales forecast for alvocidib in cancer across the seven major markets ($m), 2010-2019 81 Table 37: Abiraterone - drug profile, 2010 82 Table 38: Abiraterone: key historical events, 2004-2010 83 Table 39: Clinical development of abiraterone in cancer, 2010 84 Table 40: Sales forecast for abiraterone in cancer across the seven major markets ($m), 2010-2019 92 Table 41: BSI-201 - drug profile, 2010 94 Table 42: BSI-201: key historical events, 2006-09 94 Table 43: Clinical development of BSI-201 in cancer, 2010 95 Table 44: Sales forecast for BSI-201 in cancer across the seven major markets ($m), 2010-2019 100 Table 45: Phenoxodiol - drug profile, 2010 101 Table 46: Phenoxodiol: key historical events, 1999-2010 102 Table 47: Clinical development of phenoxodiol in cancer, 2010 103 Table 48: Trabedersen - drug profile, 2010 106 Table 49: Trabedersen: key historical events, 2002-09 106 Table 50: Clinical development of trabedersen in cancer, 2010 107 Table 51: Sales forecast for trabedersen in cancer across the seven major markets ($m), 2010-2019 112 Table 52: ZD-4054 - drug profile, 2010 113 Table 53: ZD-4054: key historical events, 2005-08 114 Table 54: Clinical development of ZD-4054 in cancer, 2010 114 Table 55: Sales forecast for ZD-4054 in cancer across the seven major markets ($m), 2010-2019 120 Table 56: Late-phase small molecule multi- targeted pipeline, 2010 122 Table 60: Sales forecasts for multi-targeted inhibitors in late-phase development for cancer in the seven major markets ($m), 2010-19 126 Table 61: Gleevec- drug profile, 2010 128 Table 62: Enzastaurin - drug profile, 2010 129 Table 63: Enzastaurin: key historical events, 2010 130 Table 64: Clinical development of enzastaurin in cancer, 2010 130 Table 65: Sales forecast for enzastaurin in cancer across the seven major markets ($m), 2010-2019 136 Table 66: Linifanib - drug profile, 2010 138 Table 67: Linifanib: key historical events 138 Table 68: Clinical development of linifanib in cancer, 2010 139 Table 69: Sales forecast for linifanib in cancer across the seven major markets ($m), 2010-2019 143 Table 70: Masitinib - drug profile, 2010 145 Table 71: Masitinib: key historical events, 2004-09 146 Table 72: Clinical development of masitinib in cancer, 2010 146 Table 73: Sales forecast for masitinib in cancer across the seven major markets ($m), 2010-2019 152 Table 74: Midostaurin - drug profile, 2010 154 Table 75: Midostaurin: key historical events, 2002-2010 154 Table 76: Clinical development of midostaurin in acute myeloid leukemia, 2010 155 Table 77: Sales forecast for midostaurin in cancer across the seven major markets ($m), 2010-2019 160 Table 78: Perifosine- drug profile, 2010 161 Table 79: Perifosine: key historical events, 1999-2010 162 Table 80: Clinical development of perifosine in cancer, 2010 163 Table 81: Phase I/II trial investigating the combination of perifosine and Velcade in heavily pretreated Hodgkin's lymphoma patients; results for Velcade (bortezomib) relapsed or refractory patients 166 Table 82: Updated results from a Phase I/II trial investigating the combination of perifosine and Velcade in heavily pretreated Hodgkin's lymphoma patients 166 Table 83: Sales forecast for perifosine in cancer across the seven major markets ($m), 2010-2019 171 Table 84: PF-2341066 - drug profile, 2010 172 Table 85: PF-2341066: key historical events, 2005-09 173 Table 86: Clinical development of PF-2341066 in cancer, 2010 174 Table 87: Sales forecast for PF-2341066 in cancer across the seven major markets ($m), 2010-2019 179 Table 88: Zactima- drug profile, 2010 180 Table 89: Zactima: key historical events, 2004-09 181 Table 90: Clinical development of perifosine in cancer, 2009 181 Table 91: Phase II results for Zactima monotherapy in metastatic hereditary medullary thyroid cancer 186 Table 92: XL-184- drug profile, 2010 194 Table 93: XL-184: key historical events, 2002-2010 195 Table 94: Clinical development of XL-184 in cancer, 2010 196 Table 95: Phase I study results for XL-184 in patients with medullary thyroid cancer 197 Table 96: Sales forecast for XL-184 in cancer across the seven major markets ($m), 2010-2019 203 Table 97: Late-phase small molecule single-target signal transduction inhibitors, 2010 204 Table 99: Sales forecasts small molecule single target signal transduction inhibitors in late phase development for cancer in the seven major markets ($m), 2010-19 206 Table 100: Tarceva - drug profile, 2010 208 Table 101: OSI-906 - drug profile, 2010 209 Table 102: OSI-906: key historical events, 2006-09 209 Table 103: Clinical development of OSI-906 in cancer, 2010 210 Table 104: PLX-4032 - drug profile, 2010 213 Table 105: PLX-4032: key historical events, 2006-2010 213 Table 106: Clinical development of PLX-4032 in cancer, 2010 214 Table 107: Sales forecast for PLX-4032 in cancer across the seven major markets ($m), 2010-2019 219 Table 108: Top 10 Phase I/ II small molecule molecular targeted therapies drug targets, 2010 222 Table 109: Datamonitor drug assessment parameters 240 [Inhaltsverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
